

Leqvio (inclisiran)
Effective 07/01/2022

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029

Overview

Leqvio is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Coverage Guidelines

Authorization may be reviewed for members new to the plan who are currently receiving treatment with Leqvio excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

Clinical Atherosclerotic Cardiovascular Disease (ASCVD)

1. Member has a history of clinical ASCVD (see Appendix A)
2. Member meets ONE of the following:
 - a. Current LDL-C level ≥ 70 mg/dL after at least three months of treatment with documentation of a high-intensity statin (if member is unable to tolerate a high-intensity statin, a moderate intensity statin will be considered)
 - b. Current LDL-C level ≥ 70 mg/dL with documented contraindication or intolerance to statins (see Appendix B and C)
3. Member will continue to receive concomitant statin therapy if there are no contraindications or intolerance
4. Member has documented intolerance, adverse event, or contraindication to Praluent.

Heterozygous Familial Hypercholesterolemia (HeFH)

1. Member has a history of HeFH with a diagnosis confirmed by ONE of the following:
 - a. Documentation of LDL-receptor mutation, familial defective apo B-100, or a PCSK9 mutation

- b. A documented history of untreated LDL-C of > 190mg/dL and meets at least ONE of the following criteria:
 - i. Presence of tendon xanthoma(s) in the member or first/second degree relative
 - ii. Family history of myocardial infarction (MI) at < 60 years in first degree relative or < 50 years in second degree relative
 - iii. Family history of total cholesterol (TC) > 290mg/dL in a first/second degree relative
 2. Member meets ONE of the following:
 - a. Current LDL-C level \geq 70mg/dL after at least three months of treatment with documentation of a high-intensity statin (if member is unable to tolerate a high-intensity statin, a moderate intensity statin will be considered)
 - b. Current LDL-C level \geq 70mg/dL with documented contraindication or intolerance to statins (see Appendix B and C)
 3. Member will continue to receive concomitant statin therapy if there are no contraindications or intolerance
 4. Member has documented intolerance, adverse event, or contraindication to Praluent.

Continuation of Therapy

Reauthorization requires physician documentation of continuation of therapy, positive response to therapy, and member has achieved maintained LDL-C reduction (e.g., LDL-C is now at goal, robust lowering of LDL-C). Documentation that member continues to receive statin therapy if there are no contraindications or intolerance.

Limitations

1. Initial approvals will be granted for 6 months.
2. Reauthorizations will be granted for 12 months

Appendix

Appendix A: Clinical ASCVD

- Acute coronary syndromes
- Myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization procedure (e.g., percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG] surgery)
- Stroke of presumed atherosclerotic origin
- Transient ischemic attack (TIA)
- Non-cardiac peripheral arterial disease (PAD) of presumed atherosclerotic origin (e.g., carotid artery stenosis, lower extremity PAD)
- Obstructive coronary artery disease (defined as fifty percent or greater stenosis on cardiac computed tomography angiogram or catheterization)
- Coronary Artery Calcium (CAC) Score \geq 1000

Appendix B. Statin-associated muscle symptoms (SAMS) and statin re-challenge

- Score of 7 or higher on the Statin-Associated Muscle Symptom Clinical Index (SAMS-CI)
- Statin-associated elevation in creatine kinase (CK) level \geq 10 times upper limit of normal (ULN)

NOTE: Statin re-challenge is NOT required for members who have experienced an elevation of CK level \geq 10 times ULN after receiving lipid-lowering therapy (LLT) with a statin.



Appendix C. Contraindications to statins

- Active liver disease, including unexplained persistent elevations in hepatic transaminase levels (e.g., alanine transaminase (ALT) level \geq 3 times ULN)
- Pregnancy or planned pregnancy
- Breastfeeding

References

1. Leqvio [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2021.
2. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. *N Engl J Med*. 2020;382:1507-1519. DOI: 10.1056/NEJMoa1912387.
3. Raal FJ, Kallend D, Kausik KR, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020; 382:1520-1530. DOI: 10.1056/NEJMoa1913805.
4. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, et al. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. *J Am Heart Assoc*. 2019; 8:e013225. DOI: 10.1161/JAHA119.013225.
5. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 — full report. *J Clin Lipidol*. 2015;9:129–169.
6. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol: report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018.
7. Min JK, Labounty TM, Gomez MJ, et al. Incremental prognostic value of coronary computed tomographic angiography over coronary artery calcium score for risk prediction of major adverse cardiac events in asymptomatic diabetic individuals. *Atherosclerosis*. 2014;232(2):298-304.
8. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Arch Med Sci*. 2015;11:1-23.
9. Mesi O, Lin C, Ahmed H, et al. Statin Intolerance and New Lipid-lowering Treatments. *Cleve Clin J Med*. 2021; 88(7)381-387. DOI: 10.3949/ccjm.88a.20165.
10. Rosenson, RS. Miller, K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation and Inter-rater Reliability. *Cardiovasc Drugs Ther*. 2017;31:179-186. DOI: 10.1007/s10557-017-6723-4.

Review History

05/18/2022 – Created and reviewed for May P&T.

